TYB-2285对主动致敏大鼠肺部过敏反应的影响。

Effect of TYB-2285 on lung anaphylaxis in actively sensitized rats.

Watanabe A, Tominaga T, Shutoh H, Hayashi H, Tsuji J, Koda A, Nagai H, Kumazawa Y, Shimada H

Department of Pharmacology, Toyobo Co. Ltd., Shiga, Japan.

Gen Pharmacol. 1997 Feb;28(2):305-9. doi: 10.1016/s0306-3623(96)00226-1.

Abstract

We examined the effect of TYB-2285 on the acute phase and the late phase of lung anaphylaxis in rats. 2. TYB-2285 (3-30 mg/kg PO) inhibited antigen-induced bronchoconstriction and TxB2 production during the acute phase of lung anaphylaxis in a dose-dependent manner. 3. Ketotifen fumarate (30 mg/kg p.o.) inhibited bronchoconstriction and TxB2 production less potently than TYB-2285. 4. TYB-2285 (30 mg/kg p.o.) inhibited the accumulation of neutrophils during the late phase of lung anaphylaxis significantly without a significant change in total cells. 5. Hydrocortisone acetate (100 mg/kg p.o.) inhibited the accumulation of total cells as potent as neutrophils.

摘要

我们研究了TYB - 2285对大鼠肺部过敏反应急性期和晚期的影响。2. TYB - 2285（口服3 - 30毫克/千克）在肺部过敏反应急性期以剂量依赖方式抑制抗原诱导的支气管收缩和血栓素B2（TxB2）的产生。3. 富马酸酮替芬（口服30毫克/千克）抑制支气管收缩和TxB2产生的效力低于TYB - 2285。4. TYB - 2285（口服30毫克/千克）在肺部过敏反应晚期显著抑制中性粒细胞的积聚，而总细胞数无显著变化。5. 醋酸氢化可的松（口服100毫克/千克）抑制总细胞积聚的效力与抑制中性粒细胞的效力相同。